Case Report of a Rare Disease: Concomitant Renal Cell Carcinoma with Cushing's Disease

Yıl 2018, , 209 - 212, 01.12.2018

Murat Çalapkulu , Özen Öz Gül , Soner Cander , Canan Ersoy , Erdinç Ertürk

https://doi.org/10.32708/uutfd.453529

Öz

Adrenocorticotropic hormone (ACTH)-secreting pituitary adenoma is the most common
cause of endogenous Cushing’s disease. Renal cell carcinoma (RCC) is the most
common renal cancer and there may be many endocrine abnormalities
associated with this cancer. Cushing’s syndrome can be observed in patients who
are diagnosed with renal cell carcinoma, although Cushing's disease is very
rare . The diagnosis of Cushing's disease is made by the evaluation of clinical
symptoms, endocrinological tests and radiological findings. The most effective
treatment for Cushing's disease is adenomal resection, but the chance of cure
with resection is lower in macroadenomas. Radiotherapy, medical treatments
(such as bromocriptine, cyproheptadine, ketaconazole, pasireotide) or bilateral
adrenalectomy may be considered in cases of not cured in the postoperative
period. In this report, we present a patient with a diagnosis of Cushing’s
disease and renal cell carcinoma.

Anahtar Kelimeler

Renal cell carcinoma, Cushing's disease, ACTH-secreting adenoma

Nadir Bir Olgu: Renal Hücreli Karsinom ile Cushing Hastalığı Birlikteliği

Öz

Hipofiz
bezinden adrenokortikotropik hormon (ACTH) salgılayan adenom, endojen Cushing hastalığının en
sık görülen nedenidir. Renal hücreli karsinom (RCC) en sık görülen böbrek
kanseridir ve bu kanser ile ilişkili birçok endokrinolojik anormallik olabilir.
Renal hücreli karsinom tanısı alan hastalarda Cushing sendromu saptanabilirken Cushing
hastalığı çok nadir görülür. Cushing hastalığının tanısı klinik
semptomlar, endokrinolojik testler ve radyolojik bulguların değerlendirilmesi
ile konur. Cushing hastalığında en etkili tedavi adenomun rezeksiyonudur ama
makroadenomlarda rezeksiyon ile kür şansı daha düşüktür. Postoperatif dönemde
kür sağlanamamış olgularda tedavi seçenekleri arasında radyoterapi, medikal
tedaviler (bromokriptin, siproheptadin, ketakonazol, pasireotide gibi) veya
bilateral adrenalektomi düşünülebilir. Burada Cushing
hastalığı ile birlikte renal hücreli karsinom tanısı konulan bir hasta
sunulacaktır.

Anahtar Kelimeler

Renal hücreli karsinom, cushing hastalığı, ACTH salgılayan adenom

Kaynakça

• 1. Cushing H. The Basophil Adenomas of the Pituitary Body. Ann R Coll Surg Engl 1969;44(4):180–1.
• 2. Howlett TA, Ress LH, Besser GM: Cushing’s syndrome. Clinics Endocrinol Metab 14;911-913, 1985.
• 3. Carpenter PC: Cushing syndrome: Update of diagnosis and management. Mayo Clin Proc 61:49-51, 1986.
• 4. Ramirez G, Gomez-Sanchez C, Meikle AW, Jubiz W: Evaluation of the hypothalamic hypophyseal adrenal axis in patients receiving long-term hemodialysis. Arch Intern Med 142:1448-1452, 1982.
• 5. Sharp NA, Devlin JT, Rimmer JM: Renal failure obfuscates the diagnosis of Cushing’s disease. JAMA 256:2564-2565, 1986.
• 6. Jang Eun L, Jun Choi I, Jai Park Y, et al. A Case of Cushing’s Disease with Renal Cell Carcinoma and End-stage Renal Disease. 2007.
• 7. Cook DM, Louriax DL: Cushing’s syndorme. Curr Ther End Met 5:142-146, 1994.
• 8. Türkiye Endokrinoloji ve Metabolizma Derneği adrenal ve gonadal hastalıklar kılavuzu 2018.
• 9. Newell-Price J, Tainer P, Besser M, Grossman A: The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing’s states. Endocr Rev 19:647-672, 1998.
• 10. Mampalam TJ, Tyrell JB, Wilson CB: Trans-sphenoidal microsurgery for Cushing’s disease. A report of 216 cases. Ann Intern Med 109:487-493, 1998.
• 11. Adachi M, Takayanagi R, Yanase T, Sakai Y, Ikuyama S, Nakagaki H, Osamura Y, Sanno N, Nawata H: Cyclic Cushing’s disease in long-term remission with a daily low dose of bromocriptine. Intern Med 35:207-211, 1996.
• 12. Palapattu GS, Kristo B, Rajfer J. Paraneoplastic syndromes in urologic malignancy: the many faces of renal cell carcinoma. Rev Urol 2002;4(4):163–70.
• 13. Riggs BL, Sprague RG. Association of Cushing’s syndrome and neoplastic disease: observations in 232 cases of Cushing’s syndrome and review of the literature. Arch Intern Med 1961;108:841–9.
• 14. Bartuska DC. Humoral manifestations of neoplasms. Semin Oncol. 1975;2:405–407.
• 15. Gsponer J, De Tribolet N, Déruaz JP, et al. Diagnosis, treatment, and outcome of pituitary tumors and other abnormal intrasellar masses. Retrospective analysis of 353 patients. Medicine (Baltimore) 1999;78(4):236–69.
• 16. Komninos J, Vlassopoulou V, Protopapa D, et al. Tumors metastatic to the pituitary gland: case report and literature review. J Clin Endocrinol Metab 2004;89(2):574–80.
• 17. Weber J, Gassel AM, Hoch A, Spring A. Concomitant renal cell carcinoma with pituitary adenoma. Acta Neurochir (Wien) 2003;145(3):227–31.
• 18. McCormick PC, Post KD, Kandji AD, Hays AP. Metastatic carcinoma to the pituitary gland. Br J Neurosurg 1989;3(1):71–9.
• 19. Gopan T, Toms SA, Prayson RA, Suh JH, Hamrahian AH, Weil RJ. Symptomatic pituitary metastases from renal cell carcinoma. Pituitary 2007;10(3):251–9.